The joint venture will commercialize and distribute selected Sobi medicines in South Korea.

The joint venture, due for incorporation in the first half of this year, is expected to enhance the Sobi and Handok collaboration, they state. Strengthening their position in the rare disease business, Handok and Sobi aim to develop, commercialize and distribute Sobi’s innovative medicines in South Korea.

“Our medicines fill a medical need in this important and highly developed market,” said Guido Oelkers, Chief Executive Officer of Sobi. “With Handok, we found a partner who combines rare disease experience with deep knowledge of the local market. We look forward to working with Handok to introduce our innovative medicines in South Korea, starting with Empaveli and Doptelet.”

Photo of Guido Oelkers: Sobi